WebMar 16, 2024 · If you aren’t enrolled in eForms, complete the fillable PDF version: General Special Authority Request (PDF, 656KB) Document your patient's clinical need for the … This table lists limited coverage drugs. Click the drug name to see Special Authority … Special Authority. Coverage for limited coverage drugs is provided through … Special Authority requests must be completed by a licensed medical … Fair PharmaCare plan. Fair PharmaCare Administration PO Box 9655 Stn Prov … WebFeb 10, 2024 · Treatment of persistent neutropenia (ANC ≤ 0.5 x 10 9 /l), and a history of severe or recurrent infections, long-term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.
Filgrastim Uses, Dosage, Side Effects, FAQ - MedicinesFAQ
WebApr 1, 2024 · PURPOSE: Temporary COVID-19 guideline recommendations have recently been issued to expand the use of colony-stimulating factors in patients with cancer with intermediate to high risk for febrile neutropenia (FN). We evaluated the cost-effectiveness of primary prophylaxis (PP) with biosimilar filgrastim-sndz in patients with intermediate risk … WebApr 21, 2024 · Filgrastim may cause serious side effects. Stop using filgrastim and call your doctor at once if you have: easy bruising, unusual bleeding, purple or red spots … cjr.b stock price tsx
Special Authority (SA) - Province of British Columbia
Web5 > 2.0 x 109/l, with the median dose frequency being 3 days per week.Long-term administration may be required to maintain the ANC > 2.0 x 109/l. Special populations Elderly patients Clinical trials with filgrastim have included a small number of elderly patients but special studies have http://www.bccancer.bc.ca/pharmacy-site/Documents/Pharmacy%20FAQs/Pharmacy-FAQ-Filgrastim-Coverage.pdf WebFilgrastim is a Limited Coverage Drug through the BC PharmaCare Special Authority Program and the indications for coverage are outlined on the Filgrastim (GRASTOFIL. … cjrc lewis and clark